|
1
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Prasad SM, Decastro GJ and Steinberg GD:
Medscape: URothelial carcinoma of the bladder: Definition,
treatment and future efforts. Nat Rev Urol. 8:631–642. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abdollah F, Gandaglia G, Thuret R,
Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF,
Perrotte P, et al: Incidence, survival and mortality rates of
stage-specific bladder cancer in united states: A trend analysis.
Cancer Epidemiol. 37:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bishr M, Lattouf JB, Latour M and Saad F:
Tumour stage on re-staging transurethral resection predicts
recurrence anad progression-free survival of patients with
high-risk non-muscle invasive bladder cancer. Can Urol Assoc J.
8:E306–E310. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yafi FA, Aprikian AG, Chin JL, Fradet Y,
Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, et
al: Contemporary outcomes of 2287 patients with bladder cancer who
were treated with radical cystectomy: A canadian multicentre
experience. BJU Int. 108:539–545. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Soloway MS: Bladder cancer: Lack of
progress in bladder cancer-what are the obstacles? Nat Rev Urol.
10:5–6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nedjadi T, Al-Maghrabi J, Assidi M, Dallol
A, Al-Kattabi H, Chaudhary A, Al-Sayyad A, Al-Ammari A, Abuzenadah
A, Buhmeida A and Al-Qahtani M: Prognostic value of HER2 status in
bladder transitional cell carcinoma revealed by both IHC and BDISH
techniques. BMC Cancer. 16:6532016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang ZY, Zhang W, Yang JJ, Song DK, Wei JX
and Gao S: Association of thymosin β4 expression with
clinicopathological parameters and clinical outcomes of bladder
cancer patients. Neoplasma. 63:991–998. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou J, Dong D, Cheng R, Wang Y, Jiang S,
Zhu Y, Fan L, Mao X, Gui Y, Li Z, et al: Aberrant expression of
KPNA2 is associated with a poor prognosis and contributes to OCT4
nuclear transportation in bladder cancer. Oncotarget.
7:72767–72776. 2016.PubMed/NCBI
|
|
10
|
van der Heijden AG, Mengual L, Lozano JJ,
Ingelmo-Torres M, Ribal MJ, Fernandez PL, Oosterwijk E, Schalken
JA, Alcaraz JA, Alcaraz A and Witjes JA: A five-gene expression
signature to predict progression in T1G3 bladder cancer. Eur J
Cancer. 64:127–136. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pignot G, Cizeron-Clairac G, Vacher S,
Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B,
Amsellem-Ouazana D and Bieche I: microRNA expression profile in a
large series of bladder tumors: identification of a 3-miRNA
signature associated with aggressiveness of muscle-invasive bladder
cancer. Int J Cancer. 132:2479–2491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Segersten U, Spector Y, Goren Y, Tabak S
and Malmström PU: The role of microRNA profiling in prognosticating
progression in Ta and T1 urinary bladder cancer. Urol Oncol.
32:613–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goto H, Kasahara K and Inagaki M: Novel
insights into Chk1 regulation by phosphorylation. Cell Struct
Funct. 40:43–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Toledo LI, Murga M and Fernandez-Capetillo
O: Targeting ATR and Chk1 kinases for cancer treatment: A new model
for new (and old) drugs. Mol Oncol. 5:368–373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Petermann E, Maya-Mendoza A, Zachos G,
Gillespie DA, Jackson DA and Caldecott KW: Chk1 requirement for
high global rates of replication fork progression during normal
vertebrate S phase. Mol Cell Biol. 26:3319–3326. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Petermann E, Woodcock M and Helleday T:
Chk1 promotes replication fork progression by controlling
replication initiation. Proc Natl Acad Sci USA. 107:pp.
16090–16095. 2010; View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Herman-Antosiewicz A, Stan SD, Hahm ER,
Xiao D and Singh SV: Activation of a novel ataxia-telangiectasia
mutated and Rad3 related/checkpoint kinase 1-dependent prometaphase
checkpoint in cancer cells by diallyl trisulfide, a promising
cancer chemopreventive constituent of processed garlic. Mol Cancer
Ther. 6:1249–1261. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Myers K, Gagou ME, Zuazua-Villar P,
Rodriguez R and Meuth M: ATR and Chk1 suppress a
caspase-3-dependent apoptotic response following DNA replication
stress. PLoS Genet. 5:e10003242009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wasylishen AR and Lozano G: Attenuating
the p53 pathway in human cancers: many means to the same end. Cold
Spring Harb Perspect Med. 6:a0262112016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vazquez A, Bond EE, Levine AJ and Bond GL:
The genetics of the p53 pathway, apoptosis and cancer therapy. Nat
Rev Drug Discov. 7:979–987. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Williams AB and Schumacher B: p53 in the
DNA-Damage-Repair Process. Cold Spring Harb Perspect Med. 6:2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Freed-Pastor WA and Prives C: Mutant p53:
One name, many proteins. Genes Dev. 26:1268–1286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Humphrey PA, Moch H, Cubilla AL, Ulbright
TM and Reuter VE: The 2016 WHO classification of tumours of the
urinary system and male genital organs-part B: Prostate and bladder
tumours. Eur Urol. 70:106–119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rath S, Connors JM, Dolman PJ, Rootman J,
Rootman DB and White VA: Comparison of American Joint Committee on
Cancer TNM-based staging system (7th edition) and Ann Arbor
Classification for predicting outcome in ocular adnexal lymphoma.
Orbit. 33:23–28. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Drayton RM and Catto JW: Molecular
mechanisms of cisplatin resistance in bladder cancer. Expert Rev
Anticancer Ther. 12:271–281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li CC, Yang JC, Lu MC, Lee CL, Peng CY,
Hsu WY, Dai YH, Chang FR, Zhang DY, Wu WJ and Wu YC: ATR-Chk1
signaling inhibition as a therapeutic strategy to enhance cisplatin
chemosensitivity in urothelial bladder cancer. Oncotarget.
7:1947–1959. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Umezawa Y, Kurosu T, Akiyama H, Wu N,
Nogami A, Nagao T and Miura O: Down regulation of Chk1 by p53 plays
a role in synergistic induction of apoptosis by chemotherapeutics
and inhibitors for Jak2 or BCR/ABL in hematopoietic cells.
Oncotarget. 7:44448–44461. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Manic G, Obrist F, Sistigu A and Vitale I:
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for
anticancer therapy. Mol Cell Oncol. 2:e10129762015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bernard JJ, Lou YR, Peng QY, Li T, Conney
AH and Lu YP: Inverse relationship between p53 and phospho-Chk1
(Ser317) protein expression in UVB-induced skin tumors in SKH-1
mice. Exp Mol Pathol. 96:126–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
